targeted-alpha-therapy
(3)
Paul Blanchfield
Paul Blanchfield is the CEO of Alpha-9 Oncology, a Boston-based clinical-stage radiopharmaceutical company developing targeted alpha and beta therapies for cancer. He took the top job in November 2025 after running Lantheus as President, following earlier operator stints at Takeda and Shire and a five-year run at McKinsey.
Philina Lee
Philina Lee, PhD is the Chief Executive Officer of AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer built on a proprietary Lead-212 platform. A biopharmaceutical executive with more than two decades in oncology, she was Chief Commercial Officer at Blueprint Medicines (acquired by Sanofi for roughly $9.5 billion) and earlier helped build the organization at Algeta that launched Xofigo, the first approved alpha therapy. Trained as a cell biologist at MIT, she took the AdvanCell helm on January 1, 2026 to lead the company's US expansion from a new Boston-area headquarters and advance its lead candidate 212Pb-ADVC001 for prostate cancer.
Philip Kantoff
Philip Kantoff is a medical oncologist who spent three decades shaping how the world treats prostate cancer, then walked away from running medicine at one of the country's largest cancer hospitals to start a company. As co-founder and CEO of Convergent Therapeutics in Cambridge, Massachusetts, he is developing CONV01-alpha, an alpha-emitting radioantibody that hunts down prostate tumor cells and irradiates them at close range. He has published more than 500 papers, been cited over 85,000 times, mentored a generation of oncology leaders, and at an age when most peers retire, raised $90 million in Series A funding to bring a new class of cancer therapy into the clinic.